[1]张 宸,金秋晨,陈永法.儿童药卫生技术评估的特殊性——以英国NICE儿童药评估为例[J].卫生经济研究,2021,38(11):51-54.
　ZHANG Chen,JIN Qiu-chen,CHEN Yong-fa.Particularity of Health Technology Assessment for Children's Drug——Taking NICE Children's Drug Assessment as an Example[J].Journal Press of Health Economics Research,2021,38(11):51-54.
点击复制

儿童药卫生技术评估的特殊性
——以英国NICE儿童药评估为例
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年11期
页码:
51-54
栏目:
卫生技术评估
出版日期:
2021-10-29

文章信息/Info

Title:
Particularity of Health Technology Assessment for Children's Drug
——Taking NICE Children's Drug Assessment as an Example
作者:
张 宸1; 金秋晨1; 陈永法1
1.中国药科大学国际医药商学院， 江苏 南京 211198
Author(s):
ZHANG Chen;  JIN Qiu-chen;  CHEN Yong-fa
School of International Pharmaceutical Business of China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
儿童药; 卫生技术评估; 儿童特殊性
Keywords:
children's drug;  health technology assessment;  child particularity
分类号:
R95
文献标志码:
A
摘要:
为了在儿童药卫生技术评估中充分体现儿童人群的特殊性，对儿童药做出更科学的价值判断，选取英国国家卫生与临床优化研究所发布的儿童药卫生技术评估指南，总结其在临床疗效、成本效益、非直接健康效益和社会价值等方面对儿童特殊性的考虑及具体体现，提出完善我国儿童药卫生技术评估的建议。
Abstract:
In order to fully reflect the particularity of children 's population and make more scientific value judgment on children 's drug in the health technology assessment of children 's drug, this paper selects the children’s medicine health technology evaluation guidelines issued by the National Institute of Health and Clinical Optimization in the United Kingdom, summarizes its considerations and specific manifestations of children's particularity in terms of clinical efficacy, cost-effectiveness, indirect health benefits and social value, and put forward suggestions for improving the health technology assessment of children 's drug in China.

参考文献/References:

[1] 胡善联.卫生技术评估在医保报销目录调整中的作用[J].世界临床药物，2020，41（12）：915-916.
[2] 赵琨，隋宾艳，郭武栋，等.卫生技术评估的国际经验及启示[J].中国卫生经济，2012，31（2）：87-89.
[3] O’ROURKE B,OORTWIJN W,SCHULLER T. Announcing the New Definition of Health Technology Assessment[J].Value in Health,2020, 23(6):824-825.
[4] 姚嘉奇，周挺，管欣，等.英国NICE卫生技术评估介绍及对我国医保目录动态调整的启示[J].中国循证医学杂志，2018，18（9）：984-989.
[5] 常峰，崔鹏磊，夏强.英国患者用药可及性方案实施经验及对我国的启示[J].中国卫生政策研究，2016，9（7）：60-65.
[6] Rawlins M,Barnett D,Stevens A.Pharmacoeconomics:NICE's approach to decision-making[J].British Journal of Clinical Pharmacology,2010,70(3):346-349.
[7] Hill J,R Pennington,Wailoo A,et al.A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents[J].Value in Health,2020,23(7).
[8] 张海军，梁云，袁妮.英国NICE罕见病用药卫生技术评估流程介绍及其启示[J].中国新药杂志，2018，27（14）：1587-1594.
[9] 伍琳，陈永法，柳婷婷.英国专利药NHS准入管理实践及其对我国的启示[J].中国医药工业杂志，2017，48（10）：1527-1533.
[10] National Institute for Health and Care Excellence.Guide to the methods of technology appraisal 2013[EB/OL].(2013-04-04)[2021-03-12].https://www.nice.org.uk/process/pmg9/chapter/foreword.

相似文献/References:

[1]黄 理,路 云,段承阿鑫.卫生技术评估在高值医用耗材供应保障中的应用价值及其实现[J].卫生经济研究,2018,(10):10.
　HUANG Li,LU Yun,DUAN Cheng-a-xin.The Application Value and Its Realization of Health Technology Assessment in the Supply Security of High-value Medical Consumables[J].Journal Press of Health Economics Research,2018,(11):10.
[2]金春林,王海银,孙 辉,等.价值医疗的概念、实践及其实现路径[J].卫生经济研究,2019,(02):6.
　JIN Chun-lin,WANG Hai-yin,SUN Hui,et al.The Concept, Progress and Practice Path of Value-based healthcare[J].Journal Press of Health Economics Research,2019,(11):6.
[3]傅 卫,赵 琨.中国卫生技术评估的发展与挑战[J].卫生经济研究,2019,(03):3.
　FU Wei,ZHAO Kun.Development and Challenges of China's Health Technology Assessment[J].Journal Press of Health Economics Research,2019,(11):3.
[4]金秋晨,张 宸,陈永法.抗肿瘤药物联合疗法价值归因探索[J].卫生经济研究,2023,40(10):74.
　JIN Qiuchen,ZHANG Chen,CHEN Yongfa.Study on the Value Attribution of Antitumor Drug Combination Therapy[J].Journal Press of Health Economics Research,2023,40(11):74.
[5]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(11):62.

更新日期/Last Update: 2021-10-29